Amniotic membrane eye therapy is a regenerative treatment for corneas that will not heal on their own. It uses tissue from the placenta’s innermost layer, which is rich in growth factors and anti-inflammatory proteins.
This therapy works differently than drops or bandages. It rebuilds the surface at the cellular level instead of masking symptoms.
Doctors typically turn to this option after other treatments have failed. Patients who reach this point often feel frustrated by repeated visits and short-lived relief, so understanding the science behind this approach can be especially helpful.
Below, you will learn how the biological components work. You will also see which conditions qualify and how doctors decide whether a patient is a good candidate.
Key Takeaways
- Amniotic membrane comes from the placenta and contains growth factors that support corneal repair.
- Corneal ulcers, chemical burns, neurotrophic keratitis, and limbal stem cell deficiency are the most common qualifying conditions.
- Severe dry eye and post-surgical complications often call for this therapy after other treatments fail.
- The procedure happens in office under topical anesthesia, with no injections required.
- This treatment works at the cellular level, so doctors reserve it for advanced cases.
How the Biological Components of Amniotic Membrane Support Ocular Surface Healing
The ocular surface cannot always repair itself after severe injury or disease. According to research in PubMed Central, amniotic tissue acts as a biological scaffold, providing mechanical support for the healing cornea. Amniotic membrane transplantation introduces biological material the eye cannot produce on its own.
The tissue comes from the placenta’s innermost layer, called the amnion. It carries anti-inflammatory cytokines, healing proteins, and neuroprotective factors that suppress inflammation and limit scarring.
These signals do more than protect the surface. They actively tell new epithelial cells to migrate and rebuild the tissue. That is why doctors call this regeneration, not a temporary patch.
What makes this tissue unique is its origin. Unlike synthetic bandages or lab-grown materials, amniotic membrane comes from a natural source that already contains the exact signals the eye recognizes. That familiarity may be part of why the body accepts and responds to it so readily.
What Role Do Growth Factors Play in Corneal Healing?
Growth factors are the most studied components in this tissue. A study in PubMed Central notes that these proteins support and activate migration, proliferation of epithelial cells. Epidermal growth factor and keratinocyte growth factor are two examples found in the membrane.
These proteins tell corneal cells to divide and move into damaged areas. They work faster than the body manages the process alone. Research also links these proteins to reduced inflammation during healing.
Immune modulation adds another layer of support. The membrane signals the immune system to calm its response at the injury site. Uncontrolled inflammation is one of the main reasons corneal haze forms after severe eye injuries.
How Is Amniotic Membrane Processed and Stored?
Tissue banks process the membrane into a cryopreserved or dehydrated graft before it reaches a patient. Tissue banks store a cryopreserved biologic graft at low temperatures to protect its proteins.
Both formats go through screening for transmissible diseases before clinical use, following standard tissue banking protocols. This screening process typically includes a review of donor health history alongside laboratory testing, similar to protocols used for other donated tissues in modern medicine.
Which Ocular Surface Diseases and Corneal Conditions Qualify for Amniotic Membrane Therapy
Not every corneal problem qualifies for this treatment. Doctors use this therapy for ocular surface diseases that have not responded to standard care. PubMed Central research on tectonic stabilization procedures lists persistent epithelial defects, neurotrophic keratopathy, bullous keratopathy among the conditions this graft addresses. The biological components work because they directly counter the damage that defines each condition.
Before recommending this treatment, doctors typically confirm that other options have already had a fair chance to work. That evaluation usually includes reviewing prior treatments, current symptoms, and how the corneal surface has responded over time.
Which Specific Conditions Respond Best?
Corneal ulcers that do not clear with antibiotic or antifungal treatment are among the most common cases. Chemical and thermal burns destroy the surface epithelium faster than the body can repair it. Recurrent corneal erosions, where the outer layer breaks down repeatedly, also respond well to this tissue repair process.
Neurotrophic keratitis is harder to treat with conventional methods. Nerve damage leaves the cornea unable to sense injury, so normal healing signals never fire. The membrane’s neuroprotective factors support nerve regeneration directly at the surface.
Limbal stem cell deficiency is another qualifying condition. This occurs when the cells that replenish the corneal epithelium are gone or badly depleted. The graft gives those remaining cells a surface to grow on.
How Is the Procedure Performed?
This grafting procedure happens in office under topical anesthesia. The procedure involves no injections or sedation. The membrane arrives as a small disk or biologic dressing. The doctor places it directly over the corneal tissue.
A PMMA ring holds the graft in place during surgical placement. A bandage contact lens goes over the top to protect the membrane and keep it secure.
The American Medical Association has assigned CPT code 65778 to this procedure. That code reflects its standing as an established ophthalmic treatment, not an experimental one.
When Dry Eye Disease and Post-Surgical Complications Call for a Regenerative Approach
Dry eye disease has a long treatment ladder. Most patients start with artificial tears, move to punctal plugs, and then try prescription drops if symptoms persist. The National Eye Institute identifies artificial tears as the most common treatment for mild dry eye. For patients who have tried those options without lasting relief, a regenerative approach becomes worth discussing.
Who Qualifies as a Candidate for This Treatment?
The candidates most likely to reach this point fall into three groups. The first group has chronic ocular surface disease that has not stabilized despite ongoing care. The second group has post-surgical dry eye, including cases that developed after cataract surgery. The third group has severe dry eye where the surface itself has broken down, not just the tear film.
Age and overall eye health also factor into candidacy. Patients with well-controlled underlying conditions, such as diabetes, often respond better to regenerative treatments than those whose systemic health remains unmanaged.
How Does This Therapy Compare to Other Dry Eye Treatments?
What sets this therapy apart from earlier options is the mechanism. Artificial tears simply add moisture to the eye. Prescription drops reduce inflammation through chemical action. This treatment rebuilds tissue architecture at the cellular level, which places it in a different category of intervention entirely.
Other advanced options exist for comparison. Autologous serum drops use a patient’s own blood to deliver growth factors topically. Surgeons reserve corneal surface reconstruction and limbal stem cell transplantation for the most severe cases.
This therapy sits between topical treatments and surgery, more involved than drops but less invasive than an operating room procedure.
For patients already following a dry eye plan, this therapy typically joins other approaches rather than replacing them. OptiLight by Lumenis is an FDA-approved light therapy that targets the gland dysfunction driving many dry eye cases. Scleral lenses hold a fluid reservoir over the surface throughout the day. Punctal plugs slow drainage to keep moisture in place.
Ocular surface care at this stage needs a treatment plan built around the specific diagnosis and the damage present. What a patient has already tried also shapes that plan.
Insurance coverage for this treatment varies by provider and by the underlying diagnosis being treated. Patients considering this option should ask their eye care team to verify benefits ahead of scheduling, since coverage often depends on whether the condition is classified as medically necessary rather than elective.
Is It Time to Explore Amniotic Membrane Eye Therapy?
Amniotic membrane eye treatment offers a proven path forward when your cornea has stopped responding to standard care. It addresses corneal ulcers, chemical burns, and neurotrophic keratitis. It also treats limbal stem cell deficiency and severe dry eye by rebuilding tissue instead of simply protecting it. These conditions all involve damage that everyday treatments can’t reverse.
If you have worked through the standard options without relief, it may be time for a different conversation. Someone who understands regenerative choices can help you weigh what’s next. A quick conversation can clarify whether your symptoms fit this treatment’s profile. It can also confirm whether another approach makes more sense first. Schedule a consultation with us to find out what your options look like!
FAQs
How is amniotic membrane placed on the eye?
The procedure happens in office under topical anesthesia, so most patients feel little discomfort. A PMMA ring holds the small tissue disk against the cornea, and a bandage contact lens goes over it. That lens protects the graft and keeps it in contact with the healing surface.
How long does the membrane stay on the eye?
Duration varies by condition, but the membrane typically stays in place for several days to a few weeks. In many cases, the tissue simply dissolves as the cornea heals underneath it. Your eye care provider sets the exact timeline based on how your surface responds to treatment.
Is amniotic membrane treatment safe, and can it transmit disease?
Tissue banks process the graft as cryopreserved or dehydrated tissue and screen it for transmissible diseases before it reaches a patient. Regulated banking standards govern this process nationwide. That screening step is required, not optional, which gives patients real peace of mind about safety.
Can amniotic membrane therapy be used alongside other dry eye treatments?
Yes, it is often one part of a broader plan that also includes punctal plugs, light therapy, or scleral lenses. The right combination depends on your specific diagnosis and how much surface damage is present. Many patients use it alongside, not instead of, their existing routine.
What is the difference between a cryopreserved amniotic membrane and a dehydrated one?
Providers store a cryopreserved amniotic membrane at low temperatures to preserve its growth factors and other active components. Dehydrated tissue goes through a different process and may retain fewer of those components. Both are used clinically today, and the choice usually depends on the condition and setting.